{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T07:48:49Z","timestamp":1753602529995,"version":"3.37.3"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Oral anticoagulants (OACs) are recommended for patients with atrial fibrillation (AFib) having CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score\u2009\u2265\u20092. However, the benefits of OAC initiation in patients with AFib and cancer at different levels of CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc is unknown. We included patients with new AFib diagnosis and a record of cancer (breast, prostate, or lung) from the 2012\u20132019 Surveillance, Epidemiology, and End Results (SEER)-Medicare database (<jats:italic>n<\/jats:italic>\u2009=\u200939,915). Risks of stroke and bleeding were compared between 5 treatment strategies: (1) initiated OAC when CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc\u2009\u2265\u20091 (<jats:italic>n<\/jats:italic>\u2009=\u20096008), (2) CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc\u2009\u2265\u20092 (<jats:italic>n<\/jats:italic>\u2009=\u20098694), (3) CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc\u2009\u2265\u20094 (<jats:italic>n<\/jats:italic>\u2009=\u200920,286), (4) CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc\u2009\u2265\u20096 (<jats:italic>n<\/jats:italic>\u2009=\u200930,944), and (5) never initiated OAC (reference group, <jats:italic>n<\/jats:italic>\u2009=\u200933,907). Confounders were adjusted using inverse probability weighting through cloning-censoring-weighting approach. Weighted pooled logistic regressions were used to estimate treatment effect [hazard ratios (HRs) and 95% confidence interval (95% CIs)]. We found that\u00a0only patients who initiated OACs at CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc\u2009\u2265\u20096 had lower risk of stroke compared without OAC initiation (HR\u20090.64, 95% CI 0.54\u20130.75). All 4 active treatment strategies had reduced risk of bleeding compared to non-initiators, with OAC initiation at CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc\u2009\u2265\u20096 being the most beneficial strategy (HR\u2009=\u20090.49, 95% CI 0.44\u20130.55). In patients with lung cancer or regional\/metastatic cancer, OAC initiation at any CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc level increased risk of stroke and did not reduce risk of bleeding (except for Regimen 4). In conclusion,\u00a0among cancer patients with new AFib diagnosis, OAC initiation at higher risk of stroke (CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score\u2009\u2265\u20096) is more beneficial in preventing ischemic stroke and bleeding. Patients with advanced cancer or low life-expectancy may initiate OACs when CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score\u2009\u2265\u20096.<\/jats:p>","DOI":"10.1007\/s11239-024-02958-3","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T05:54:28Z","timestamp":1710914068000},"page":"638-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Benefit and risk of oral anticoagulant initiation strategies in patients with atrial fibrillation and cancer: a target trial emulation using the SEER-Medicare database"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8654-5444","authenticated-orcid":false,"given":"Bang","family":"Truong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Hornsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiahung","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4624-9963","authenticated-orcid":false,"given":"Jingjing","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"issue":"23","key":"2958_CR1","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.114.008201","volume":"129","author":"NJ Patel","year":"2014","unstructured":"Patel NJ, Deshmukh A, Pant S et al (2014) Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation 129(23):2371\u20132379","journal-title":"Circulation"},{"issue":"10","key":"2958_CR2","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A et al (2019) Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation 139(10):e56\u2013e528","journal-title":"Circulation"},{"key":"2958_CR3","unstructured":"Centers for Disease Control and Prevention - National Center for Health Statistics (2019) About multiple cause of death, 1999\u20132019. https:\/\/wonder.cdc.gov\/mcd-icd10.html. Accessed 14 Oct 2021"},{"issue":"16","key":"2958_CR4","doi-asserted-by":"publisher","first-page":"e750","DOI":"10.1161\/CIR.0000000000000748","volume":"141","author":"MK Chung","year":"2020","unstructured":"Chung MK, Eckhardt LL, Chen LY et al (2020) Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. Circulation 141(16):e750\u2013e772","journal-title":"Circulation"},{"issue":"10","key":"2958_CR5","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122(10):1712\u20131723","journal-title":"Blood"},{"issue":"10","key":"2958_CR6","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","volume":"100","author":"P Prandoni","year":"2002","unstructured":"Prandoni P, Lensing AWA, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100(10):3484\u20133488","journal-title":"Blood"},{"issue":"3","key":"2958_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/ehjqcco\/qcx004","volume":"3","author":"C Melloni","year":"2017","unstructured":"Melloni C, Shrader P, Carver J et al (2017) Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry. Eur Heart J Qual Care Clin Outcomes 3(3):192\u2013197","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"16","key":"2958_CR8","doi-asserted-by":"publisher","first-page":"e008987","DOI":"10.1161\/JAHA.118.008987","volume":"7","author":"CL Fanola","year":"2018","unstructured":"Fanola CL, Ruff CT, Murphy SA et al (2018) Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF-TIMI 48 trial. J Am Heart Assoc 7(16):e008987","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2958_CR9","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA, Chung MK, Armbruster AL et al (2024) 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation 149(1):e1\u2013e156","journal-title":"Circulation"},{"issue":"12","key":"2958_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1200\/JOP.18.00592","volume":"15","author":"M Sorigue","year":"2019","unstructured":"Sorigue M, Miljkovic MD (2019) Atrial fibrillation and stroke risk in patients with cancer: a primer for oncologists. J Oncol Pract 15(12):641\u2013650","journal-title":"J Oncol Pract"},{"issue":"1","key":"2958_CR11","first-page":"58","volume":"22","author":"A Atterman","year":"2020","unstructured":"Atterman A, Friberg L, Asplund K, Engdahl J (2020) Net benefit of oral anticoagulants in patients with atrial fibrillation and active cancer: a nationwide cohort study. EP Europace 22(1):58\u201365","journal-title":"EP Europace"},{"issue":"5","key":"2958_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaccao.2020.09.008","volume":"2","author":"MG Fradley","year":"2020","unstructured":"Fradley MG, Ellenberg K, Alomar M et al (2020) Patterns of anticoagulation use in patients with cancer with atrial fibrillation and\/or atrial flutter. JACC Cardio Oncol 2(5):747\u2013754","journal-title":"JACC Cardio Oncol"},{"key":"2958_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejim.2018.10.012","volume":"59","author":"VL Malavasi","year":"2019","unstructured":"Malavasi VL, Fantecchi E, Gianolio L et al (2019) Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality. Eur J Intern Med 59:27\u201333","journal-title":"Eur J Intern Med"},{"issue":"16","key":"2958_CR14","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.jacc.2018.07.077","volume":"72","author":"WT O\u2019Neal","year":"2018","unstructured":"O\u2019Neal WT, Claxton JS, Sandesara PB et al (2018) Provider specialty, anticoagulation, and stroke risk in patients with atrial fibrillation and cancer. J Am Coll Cardiol 72(16):1913\u20131922","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2958_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2):263\u2013272","journal-title":"Chest"},{"key":"2958_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2147\/VHRM.S187656","volume":"15","author":"J Seelig","year":"2019","unstructured":"Seelig J, Pisters R, Hemels ME, Huisman MV, Ten Cate H, Alings M (2019) When to withhold oral anticoagulation in atrial fibrillation - an overview of frequent clinical discussion topics. Vasc Health Risk Manag 15:399\u2013408","journal-title":"Vasc Health Risk Manag"},{"issue":"5","key":"2958_CR17","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/phar.2679","volume":"42","author":"S Ardeshirrouhanifard","year":"2022","unstructured":"Ardeshirrouhanifard S, An H, Goyal RK et al (2022) Use of oral anticoagulants among individuals with cancer and atrial fibrillation in the United States, 2010\u20132016. Pharmacother J Hum Pharmacol Drug Ther 42(5):375\u2013386","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"issue":"6","key":"2958_CR18","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10654-017-0293-4","volume":"32","author":"JA Labrecque","year":"2017","unstructured":"Labrecque JA, Swanson SA (2017) Target trial emulation: teaching epidemiology and beyond. Eur J Epidemiol 32(6):473\u2013475","journal-title":"Eur J Epidemiol"},{"issue":"8","key":"2958_CR19","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Robins JM (2016) Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol 183(8):758\u2013764","journal-title":"Am J Epidemiol"},{"key":"2958_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Sauer BC, Hern\u00e1ndez-D\u00edaz S, Platt R, Shrier I (2016) Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol 79:70\u201375","journal-title":"J Clin Epidemiol"},{"key":"2958_CR21","unstructured":"National Cancer Institute (2021) Overview of the surveillance, epidemiology, and end results (SEER) Program. https:\/\/seer.cancer.gov\/about\/overview.html. Accessed 27 Dec 2021"},{"issue":"8 Suppl","key":"2958_CR22","first-page":"Iv","volume":"40","author":"JL Warren","year":"2002","unstructured":"Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(8 Suppl):Iv\u20133","journal-title":"Med Care"},{"issue":"Suppl 1","key":"2958_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/pds.2317","volume":"21","author":"PN Jensen","year":"2012","unstructured":"Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S (2012) A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf 21(Suppl 1):141\u2013147","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"2958_CR24","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139\u20131151","journal-title":"N Engl J Med"},{"issue":"10","key":"2958_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883\u2013891","journal-title":"N Engl J Med"},{"key":"2958_CR26","doi-asserted-by":"publisher","first-page":"k182","DOI":"10.1136\/bmj.k182","volume":"360","author":"MA Hern\u00e1n","year":"2018","unstructured":"Hern\u00e1n MA (2018) How to estimate the effect of treatment duration on survival outcomes using observational data. BMJ 360:k182\u2013k182","journal-title":"BMJ"},{"issue":"3","key":"2958_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/pds.2041","volume":"20","author":"RK Garg","year":"2011","unstructured":"Garg RK, Glazer NL, Wiggins KL et al (2011) Ascertainment of warfarin and aspirin use by medical record review compared with automated pharmacy data. Pharmacoepidemiol Drug Saf 20(3):313\u2013316","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"2958_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jaccao.2021.06.004","volume":"3","author":"S Deitelzweig","year":"2021","unstructured":"Deitelzweig S, Keshishian AV, Zhang Y et al (2021) Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active Cancer. JACC Cardio Oncol 3(3):411\u2013424","journal-title":"JACC Cardio Oncol"},{"issue":"1","key":"2958_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/CIRCOUTCOMES.113.000371","volume":"8","author":"JL Thigpen","year":"2015","unstructured":"Thigpen JL, Dillon C, Forster KB et al (2015) Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation. Circ Cardiovasc Qual Outcomes 8(1):8\u201314","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"6","key":"2958_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/pds.2109","volume":"20","author":"A Cunningham","year":"2011","unstructured":"Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA (2011) An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 20(6):560\u2013566","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"2958_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","volume":"2","author":"S Shah","year":"2018","unstructured":"Shah S, Norby FL, Datta YH et al (2018) Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv 2(3):200\u2013209","journal-title":"Blood Adv"},{"key":"2958_CR32","unstructured":"National Cancer Institute. Division of Cancer Control and Population Sciences (DCCPS) (2023) NCI comorbidity index overview. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html. Accessed 10 Jan 2023"},{"key":"2958_CR33","unstructured":"The Surveillance E (2023) Published, and end results (SEER) program,. observational research in oncology toolbox. https:\/\/seer.cancer.gov\/oncologytoolbox\/. Accessed 15 Feb 2023"},{"issue":"6","key":"2958_CR34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1001\/jamasurg.2018.0501","volume":"153","author":"KM Doll","year":"2018","unstructured":"Doll KM, Rademaker A, Sosa JA (2018) Practical guide to surgical data sets: surveillance, epidemiology, and end results (SEER) database. JAMA Surg 153(6):588\u2013589","journal-title":"JAMA Surg"},{"issue":"Supplement 1","key":"2958_CR35","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1182\/blood-2022-156895","volume":"140","author":"V Iyengar","year":"2022","unstructured":"Iyengar V, Patell R, Ren S et al (2022) Bleeding risk in atrial fibrillation and thrombocytopenia: a propensity matched Cohort study. Blood 140(Supplement 1):345\u2013346","journal-title":"Blood"},{"issue":"8","key":"2958_CR36","doi-asserted-by":"publisher","first-page":"e248","DOI":"10.1016\/j.amjmed.2022.03.011","volume":"135","author":"YH Yeh","year":"2022","unstructured":"Yeh YH, Chan YH, Chen SW et al (2022) Oral anticoagulant use for patients with atrial fibrillation with concomitant anemia and\/or thrombocytopenia. Am J Med 135(8):e248\u2013e256","journal-title":"Am J Med"},{"issue":"3","key":"2958_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.6000\/1929-6029.2015.04.03.7","volume":"4","author":"Y Liu","year":"2015","unstructured":"Liu Y, De A (2015) Multiple imputation by fully conditional specification for dealing with missing data in a large epidemiologic study. Int J Stat Med Res 4(3):287\u2013295","journal-title":"Int J Stat Med Res"},{"issue":"6","key":"2958_CR38","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1093\/ije\/dyv295","volume":"45","author":"LE Cain","year":"2016","unstructured":"Cain LE, Saag MS, Petersen M et al (2016) Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy. Int J Epidemiol 45(6):2038\u20132049","journal-title":"Int J Epidemiol"},{"issue":"2","key":"2958_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.hrthm.2018.08.023","volume":"16","author":"J Park","year":"2019","unstructured":"Park J, Cha MJ, Choi YJ et al (2019) Prognostic efficacy of platelet count in patients with nonvalvular atrial fibrillation. Heart Rhythm 16(2):197\u2013203","journal-title":"Heart Rhythm"},{"issue":"21","key":"2958_CR40","doi-asserted-by":"publisher","first-page":"e012596","DOI":"10.1161\/JAHA.119.012596","volume":"8","author":"D Pastori","year":"2019","unstructured":"Pastori D, Antonucci E, Violi F et al (2019) Thrombocytopenia and mortality risk in patients with atrial fibrillation: an analysis from the start registry. J Am Heart Association 8(21):e012596","journal-title":"J Am Heart Association"},{"issue":"1","key":"2958_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1515\/em-2012-0006","volume":"2","author":"Y Xiao","year":"2013","unstructured":"Xiao Y, Moodie EE, Abrahamowicz M (2013) Comparison of approaches to weight truncation for marginal structural Cox models. Epidemiol Methods 2(1):1\u201320","journal-title":"Epidemiol Methods"},{"issue":"1","key":"2958_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G et al (2022) An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J 15(1):14\u201320","journal-title":"Clin Kidney J"},{"issue":"2","key":"2958_CR43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jaccao.2022.08.014","volume":"5","author":"A Leader","year":"2023","unstructured":"Leader A, Mendelson Cohen N, Afek S et al (2023) Arterial thromboembolism in patients with AF and CHA2DS2-VASc score 0\u20132 with and without Cancer. JACC Cardio Oncol 5(2):174\u2013185","journal-title":"JACC Cardio Oncol"},{"issue":"2","key":"2958_CR44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jaccao.2023.01.007","volume":"5","author":"T L\u00f3pez-Fern\u00e1ndez","year":"2023","unstructured":"L\u00f3pez-Fern\u00e1ndez T (2023) CHA(2)DS(2)-VASc score in cardio-oncology: sharpening the rules. JACC Cardio Oncol 5(2):186\u2013188","journal-title":"JACC Cardio Oncol"},{"issue":"7","key":"2958_CR45","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","volume":"11","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Solomon DH, Kim SC (2015) Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 11(7):437\u2013441","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"2958_CR46","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1158\/1055-9965.EPI-22-0495","volume":"31","author":"ED Duchesneau","year":"2022","unstructured":"Duchesneau ED, Jackson BE, Webster-Clark M et al (2022) The timing, the treatment, the question: comparison of epidemiologic approaches to minimize Immortal Time bias in real-world data using a surgical oncology example. Cancer Epidemiol Biomarkers Prev 31(11):2079\u20132086","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"2958_CR47","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1634\/theoncologist.9-5-561","volume":"9","author":"J Pereira","year":"2004","unstructured":"Pereira J, Phan T (2004) Management of bleeding in patients with advanced cancer. Oncologist 9(5):561\u2013570","journal-title":"Oncologist"},{"issue":"8","key":"2958_CR48","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","volume":"70","author":"BB Navi","year":"2017","unstructured":"Navi BB, Reiner AS, Kamel H et al (2017) Risk of arterial thromboembolism in patients with Cancer. J Am Coll Cardiol 70(8):926\u2013938","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2958_CR49","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1177\/2047487318759858","volume":"25","author":"M D\u2019Souza","year":"2018","unstructured":"D\u2019Souza M, Carlson N, Fosb\u00f8l E et al (2018) CHA2DS2-VASc score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer. Eur J Prev Cardiol 25(6):651\u2013658","journal-title":"Eur J Prev Cardiol"},{"key":"2958_CR50","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.amjcard.2022.06.044","volume":"180","author":"S Raposeiras-Roubin","year":"2022","unstructured":"Raposeiras-Roubin S, Abu-Assi E, March\u00e1n A et al (2022) Validation of embolic and bleeding risk scores in patients with atrial fibrillation and cancer. Am J Cardiol 180:44\u201351","journal-title":"Am J Cardiol"},{"issue":"8","key":"2958_CR51","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/ehjqcco\/qcac090","volume":"9","author":"A Matetic","year":"2023","unstructured":"Matetic A, Mohamed MO, Essien UR et al (2023) Association between cancer, CHA2DS2VASc risk, and in-hospital ischaemic stroke in patients hospitalized for atrial fibrillation. Eur Heart J Qual Care Clin Outcomes 9(8):749\u2013757","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2958_CR52","first-page":"101072","volume":"41","author":"B Bungo","year":"2022","unstructured":"Bungo B, Chaudhury P, Arustamyan M et al (2022) Better prediction of stroke in atrial fibrillation with incorporation of cancer in CHA(2)DS(2)VASC score: CCHA(2)DS(2)VASC score. Int J Cardiol Heart Vasc 41:101072","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"2","key":"2958_CR53","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"CT January","year":"2019","unstructured":"January CT, Wann LS, Calkins H et al (2019) 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation 140(2):e125\u2013e151","journal-title":"Circulation"},{"issue":"41","key":"2958_CR54","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al (2022) 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J 43(41):4229\u20134361","journal-title":"Eur Heart J"},{"issue":"6","key":"2958_CR55","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/eurjpc\/zwaa054","volume":"28","author":"G Boriani","year":"2021","unstructured":"Boriani G, Lee G, Parrini I et al (2021) Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management. Eur J Prev Cardiol 28(6):611\u2013621","journal-title":"Eur J Prev Cardiol"},{"key":"2958_CR56","unstructured":"National Cancer Institute. Division of Cancer Control and Population Sciences (2023) Measures that are limited or not available in the data. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/measures.html. Accessed 13 June 2023"},{"key":"2958_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092574","author":"A Cereda","year":"2023","unstructured":"Cereda A, Lucreziotti S, Franchina AG et al (2023) Systematic review and meta-analysis of oral anticoagulant therapy in atrial fibrillation cancer patients. Cancers. https:\/\/doi.org\/10.3390\/cancers15092574","journal-title":"Cancers"},{"issue":"12","key":"2958_CR58","doi-asserted-by":"publisher","first-page":"e008951","DOI":"10.1161\/CIRCOUTCOMES.122.008951","volume":"15","author":"HB Mehta","year":"2022","unstructured":"Mehta HB, An H, Ardeshirrouhanifard S, Raji MA, Alexander GC, Segal JB (2022) Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among adults with cancer and atrial fibrillation. Circ Cardiovasc Qual Outcomes 15(12):e008951","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"28","key":"2958_CR59","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA (2015) Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34(28):3661\u20133679","journal-title":"Stat Med"},{"issue":"2","key":"2958_CR60","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2202\/1557-4679.1212","volume":"6","author":"LE Cain","year":"2010","unstructured":"Cain LE, Robins JM, Lanoy E, Logan R, Costagliola D, Hern\u00e1n MA (2010) When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat 6(2):18","journal-title":"Int J Biostat"},{"issue":"8","key":"2958_CR61","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/jth.14475","volume":"17","author":"K Adelborg","year":"2019","unstructured":"Adelborg K, Corraini P, Darvalics B et al (2019) Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study. J Thromb Haemost 17(8):1305\u20131318","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2958_CR62","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.clml.2017.09.008","volume":"18","author":"C Del Prete","year":"2018","unstructured":"Del Prete C, Kim T, Lansigan F, Shatzel J, Friedman H (2018) The epidemiology and clinical associations of stroke in patients with acute myeloid leukemia: a review of 10,972 admissions from the 2012 National Inpatient Sample. Clin Lymphoma Myeloma Leuk 18(1):74-77e71","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"2958_CR63","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E et al (2021) BNT162b2 mRNA Covid-19 vaccine in a Nationwide Mass Vaccination setting. N Engl J Med 384(15):1412\u20131423","journal-title":"N Engl J Med"},{"issue":"1","key":"2958_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamainternmed.2020.6252","volume":"181","author":"S Gupta","year":"2021","unstructured":"Gupta S, Wang W, Hayek SS et al (2021) Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med 181(1):41\u201351","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2958_CR65","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/infdis\/jiab330","volume":"224","author":"K Cho","year":"2021","unstructured":"Cho K, Keithly SC, Kurgansky KE et al (2021) Early convalescent plasma therapy and mortality among US veterans hospitalized with nonsevere COVID-19: an observational analysis emulating a target trial. J Infect Dis 224(6):967\u2013975","journal-title":"J Infect Dis"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02958-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-02958-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-02958-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T13:12:35Z","timestamp":1713445955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-02958-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":65,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["2958"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-02958-3","relation":{},"ISSN":["1573-742X"],"issn-type":[{"type":"electronic","value":"1573-742X"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"6 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest to report for all authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was granted exemption by the Auburn University institutional review board (IRB) and the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}